검색
Xencor Inc
XNCR관심 목록에 추가
20.210USD
-1.280-5.96%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
1.50B시가총액
손실P/E TTM
자세한 내용은 Xencor Inc 회사
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc 정보
종목 코드 XNCR
회사 이름Xencor Inc
상장일Dec 03, 2013
CEODahiyat (Bassil I)
직원 수250
유형Ordinary Share
회계 연도 종료Dec 03
주소465 N. Halstead St.
도시PASADENA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호91107
전화16263055900
웹사이트https://xencor.com/
종목 코드 XNCR
상장일Dec 03, 2013
CEODahiyat (Bassil I)
Xencor Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
11.32K
+42.63%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
10.32K
+46.76%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
10.30K
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
11.32K
+42.63%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
10.32K
+46.76%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
10.30K
--
자주 묻는 질문
Xencor Inc의 상위 5대 주주는 누구인가요?
Xencor Inc의 상위 5대 주주는 다음과 같습니다: Dr. John R. Desjarlais, Ph.D.
Xencor Inc의 최대 수익원은 무엇인가요?
2026Q4 기준, Xencor Inc의 Royalties 부문이 가장 높은 매출을 기록했으며, 금액은 80.28M로 전체 매출의 63.93%를 차지했습니다.